101 related articles for article (PubMed ID: 28685736)
1. Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer.
Ye L; Yang ZH; Fang SR; Gu W
Chin Med J (Engl); 2017 Jul; 130(14):1757-1758. PubMed ID: 28685736
[No Abstract] [Full Text] [Related]
2. Generalized eczema craquelé (asteatotic dermatitis) associated with pemetrexed treatment.
Chu CH; Chou CY; Lin FL
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e81-e83. PubMed ID: 26416293
[No Abstract] [Full Text] [Related]
3. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
4. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
[TBL] [Abstract][Full Text] [Related]
5. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
Lal R; Hillerdal GN; Shah RN; Crosse B; Thompson J; Nicolson M; Vikström A; Potter VA; Visseren-Grul C; Lorenzo M; D'yachkova Y; Bourayou N; Summers YJ
Lung Cancer; 2015 Aug; 89(2):154-60. PubMed ID: 26101013
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
Hata A; Katakami N; Hattori Y; Tanaka K; Fujita S; Kotani Y; Nishimura T; Imamura F; Yokota S; Satouchi M; Monden K; Otsuka K; Nishiyama A; Tsubouchi K; Kaneda T; Yoshioka H; Morita S; Negoro S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):689-695. PubMed ID: 28280972
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
Takagi Y; Hosomi Y; Nagamata M; Watanabe K; Takahashi S; Nakahara Y; Yomota M; Sunami K; Okuma Y; Shimokawa T; Okamura T
Cancer Chemother Pharmacol; 2016 Mar; 77(3):559-64. PubMed ID: 26821156
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer.
Ikesue H; Watanabe H; Hirano M; Chikamori A; Suetsugu K; Ryokai Y; Egashira N; Yamada T; Ikeda M; Iwama E; Harada T; Takayama K; Nakanishi Y; Masuda S
Biol Pharm Bull; 2015; 38(8):1192-8. PubMed ID: 26235582
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
[TBL] [Abstract][Full Text] [Related]
12. Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer.
Jung YD; Lee SB; Jung YW; Song JS; Woo IS
Korean J Intern Med; 2017 Sep; 32(5):923-925. PubMed ID: 28298078
[No Abstract] [Full Text] [Related]
13. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
Igawa S; Sato Y; Ishihara M; Kasajima M; Kusuhara S; Nakahara Y; Otani S; Fukui T; Katagiri M; Sasaki J; Masuda N
Asian Pac J Cancer Prev; 2016; 17(7):3249-53. PubMed ID: 27509958
[TBL] [Abstract][Full Text] [Related]
14. Lipodermatosclerosis secondary to pemetrexed use.
Shuster M; Morley K; Logan J; Sequist LV; Shaw A; Fidias P; Kroshinsky D
J Thorac Oncol; 2015 Mar; 10(3):e11-2. PubMed ID: 25695225
[No Abstract] [Full Text] [Related]
15. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
Zhong A; Xiong X; Shi M; Xu H
Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
[TBL] [Abstract][Full Text] [Related]
16. Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study.
Chang GC; Tsai CM; Hsia TC; Yang CH; Abdulnabi R; Blair JM; Linn C
J Formos Med Assoc; 2013 Sep; 112(9):518-26. PubMed ID: 24060197
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed and interstitial lung disease.
Adhikari B; Dongol RM; Baral D; Hewett Y; Shah BK
Acta Oncol; 2016; 55(4):521-2. PubMed ID: 26366501
[No Abstract] [Full Text] [Related]
18. Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.
Miyahara T; Sueoka-Aragane N; Iwanaga K; Ureshino N; Komiya K; Nakamura T; Nakashima C; Abe T; Matsunaga H; Kimura S
Med Oncol; 2017 Nov; 34(12):195. PubMed ID: 29124473
[TBL] [Abstract][Full Text] [Related]
19. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Gautschi O; Rothschild SI; Li Q; Matter-Walstra K; Zippelius A; Betticher DC; Früh M; Stahel RA; Cathomas R; Rauch D; Pless M; Peters S; Froesch P; Zander T; Schneider M; Biaggi C; Mach N; Ochsenbein AF;
Clin Lung Cancer; 2017 May; 18(3):303-309. PubMed ID: 27993482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
